



Fax completed form to: (855) 840-1678  
 If this is an URGENT request, please call (800) 882-4462  
 (800.88.CIGNA)

## Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera (trastuzumab)

| PHYSICIAN INFORMATION  |  |                       | PATIENT INFORMATION  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
|--|--|-----------------------|--|----------------------|------------------|--|--|--|--|---|---|---------------------------------------|---------------------------------------|--|--|--|--|
| * Physician Name:  |  |                       | *Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.* |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| Specialty:   | * DEA, NPI or TIN:                       |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| Office Contact Person:   |  |                       | * Patient Name:  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| Office Phone:  |  |                       | * Cigna ID:  |                      | * Date of Birth: |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| Office Fax:  |  |                       | * Patient Street Address:  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| Office Street Address:   |  |                       | City:  | State:               | Zip:             |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| City:  | State:                                   | Zip:                  | Patient Phone:   |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <b>Urgency:</b><br><input type="checkbox"/> Standard <span style="margin-left: 200px;"><input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)</span>  |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <b>Medication Requested:</b> <table style="width: 100%; border: none;"> <tr> <td><input type="checkbox"/> Herceptin 150mg</td> <td><input type="checkbox"/> Herceptin 440mg</td> </tr> <tr> <td><input type="checkbox"/> Herzuma 150mg</td> <td><input type="checkbox"/> Herzuma 420mg</td> </tr> <tr> <td><input type="checkbox"/> Kanjinti 150mg</td> <td><input type="checkbox"/> Kanjinti 420mg</td> </tr> <tr> <td><input type="checkbox"/> Ogivri 150mg</td> <td><input type="checkbox"/> Ogivri 420mg</td> </tr> <tr> <td><input type="checkbox"/> Ontruzant 150mg</td> <td><input type="checkbox"/> Ontruzant 420mg</td> </tr> <tr> <td><input type="checkbox"/> Trazimera 420mg</td> <td></td> </tr> </table> |  |                       |  |                      |                  | <input type="checkbox"/> Herceptin 150mg | <input type="checkbox"/> Herceptin 440mg | <input type="checkbox"/> Herzuma 150mg | <input type="checkbox"/> Herzuma 420mg | <input type="checkbox"/> Kanjinti 150mg | <input type="checkbox"/> Kanjinti 420mg | <input type="checkbox"/> Ogivri 150mg | <input type="checkbox"/> Ogivri 420mg | <input type="checkbox"/> Ontruzant 150mg | <input type="checkbox"/> Ontruzant 420mg | <input type="checkbox"/> Trazimera 420mg |  |
| <input type="checkbox"/> Herceptin 150mg   | <input type="checkbox"/> Herceptin 440mg |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <input type="checkbox"/> Herzuma 150mg   | <input type="checkbox"/> Herzuma 420mg   |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <input type="checkbox"/> Kanjinti 150mg  | <input type="checkbox"/> Kanjinti 420mg  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <input type="checkbox"/> Ogivri 150mg  | <input type="checkbox"/> Ogivri 420mg    |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <input type="checkbox"/> Ontruzant 150mg   | <input type="checkbox"/> Ontruzant 420mg |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <input type="checkbox"/> Trazimera 420mg   |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| Dose:  |  | Frequency of therapy: |  | Duration of therapy: |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| Will this medication be given concurrently with other agents? <input type="checkbox"/> Yes <input type="checkbox"/> No <span style="margin-left: 20px;">If yes, please specify:</span>   |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| What is your patient's current weight?   |  |                       | ICD10:   |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| Is this a new start or continuation of therapy? <input type="checkbox"/> new start <input type="checkbox"/> continuation of therapy <span style="margin-left: 20px;">Start date:</span><br>(if new start) Does your patient have documentation of trials with Kanjinti (trastuzumab-anns) AND Trazimera (trastuzumab-qyyp)?<br><input type="checkbox"/> Yes <input type="checkbox"/> No  |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <b>Where will this medication be obtained?</b><br><input type="checkbox"/> Accredo Specialty Pharmacy** <span style="margin-left: 300px;"><input type="checkbox"/> Retail pharmacy</span><br><input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <span style="margin-left: 200px;"><input type="checkbox"/> Home Health / Home Infusion vendor</span><br><input type="checkbox"/> Other (please specify): <span style="margin-left: 200px;">**Cigna's nationally preferred specialty pharmacy</span>  |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <i>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1640 Century Center Pkwy, Memphis, TN 38134-8822   NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</i>   |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <b>Facility and/or doctor dispensing and administering medication:</b><br>Facility Name: <span style="margin-left: 150px;">State:</span> <span style="margin-left: 150px;">Tax ID#:</span><br>Address (City, State, Zip Code):   |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <b>NOTE:</b> Per some Cigna plans, infusion of medication MUST occur in the lowest cost, medically appropriate setting   |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| Is this infusion occurring in a facility affiliated with hospital outpatient setting? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No</span>  |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| If yes- Is this patient a candidate for re-direction to an alternate setting (such as AIS, MDO, home) with assistance of a Specialty Care Option Case Manager? <input type="checkbox"/> Yes <input type="checkbox"/> No (provide medical necessity rationale):   |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| <b>Is your patient a candidate for home infusion?</b> <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span><br><b>Does the physician have an in-office infusion site?</b> <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span>  |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |
| Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <span style="float: right;"><input type="checkbox"/> Yes <input type="checkbox"/> No</span>   |  |                       |  |                      |                  |  |  |  |  |   |   |                                       |                                       |  |  |  |  |

**What is your patient's diagnosis?**

- breast cancer
- colorectal cancer (CRC)
- endometrial carcinoma
- gastric or gastroesophageal junction adenocarcinoma
- leptomeningeal metastases from breast cancer
- salivary gland tumors
- other (please specify):

**Clinical Information**

Does your patient have HER2-positive disease? Yes  No

(if CRC) Does your patient have the wild-type KRAS gene (RAS-WT)? Yes  No

(if CRC) Does your patient have unresectable advanced or metastatic disease? Yes  No

(if CRC) Has your patient received other therapy for this diagnosis before requesting/using this medication? Yes  No

(if previously treated) Has your patient been treated with a human epidermal growth factor receptor-2 (HER2) inhibitor (like Enhertu, Nerlynx, Kadcyla, Perjeta, Tykerb, Vizimpro) for this diagnosis before starting therapy with Herceptin or one of its biosimilars (Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera)? **Notes: Please answer "no" if only switching from Herceptin to a biosim (Herzuma, Ogivri, Ontruzant, Kanjinti, or Trazimera) OR vice versa.** Yes  No

(if previously treated) Has your patient previously been treated with an oxaliplatin-based therapy without irinotecan (Camptosar) for this diagnosis? Yes  No

(if no oxaliplatin therapy without irinotecan) Has your patient been treated with irinotecan (Camptosar)-based therapy without oxaliplatin for this diagnosis? Yes  No

(if no irinotecan therapy without oxaliplatin) Has your patient been treated with FOLFOXIRI (fluorouracil [Adrucil, 5FU], leucovorin, oxaliplatin, and irinotecan [Camptosar]) regimen for this diagnosis? Yes  No

(if no FOLFOXIRI) Has your patient previously been treated with a fluoropyrimidine (like capecitabine [Xeloda], floxuridine, or fluorouracil [Adrucil, 5FU]) without irinotecan (Camptosar) or oxaliplatin for this diagnosis? Yes  No

(if gastric/GEJ adenocarcinoma) Does your patient have advanced or metastatic disease? Yes  No

(if gastric/GEJ adenocarcinoma) What is your patient's performance status (PS)?

- PS 0, 1 or 2
- PS 3 or 4
- Unknown

(if endometrial carcinoma) Does your patient have advanced or recurrent disease? Yes  No

(if endometrial carcinoma) Will the requested drug be taken in combination with carboplatin and paclitaxel (Abraxane)?

Yes  No

(if salivary gland tumors and requesting Herceptin) Does your patient have recurrent disease?

Yes  No

(if salivary gland tumors and requesting Herceptin) Does your patient have distant metastases?

Yes  No

(if salivary gland tumors and requesting Herceptin) What is your patient's performance status (PS)?

- PS 0, 1, 2 or 3
- PS 4
- Unknown

**Additional pertinent information** (including disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Save Time! Submit Online at:** [www.covermymeds.com/main/prior-authorization-forms/cigna/](http://www.covermymeds.com/main/prior-authorization-forms/cigna/) or via SureScripts in your EHR.

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at [cigna.com](http://cigna.com).*

v070121

*"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005*